Ginsburg, I. & Koren, E. Are histones real pathogenic agents in sepsis? Nat. Rev. Immunol. http://dx.doi.org/10.1038/nri.2017.156 (2017)
van der Poll, T. et al. The immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 17, 407–420 (2017).
Chan, J. K. et al. Alarmins: awaiting a clinical response. J. Clin. Invest. 122, 2711–2719 (2012).
Deutschman, C. S. & Tracey, K. J. Sepsis: current dogma and new perspectives. Immunity 40, 463–475 (2014).
Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139–162 (2011).
Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042–1049 (2007).
van Zoelen, M. A. et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am. J. Respir. Crit. Care Med. 180, 1098–1106 (2009).
Qiang, X. et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat. Med. 19, 1489–1495 (2013).
Boyapati, R. K. et al. Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. F1000Res 6, 169 (2017).
Xu, H. et al. Role of the IL-33-ST2 axis in sepsis. Mil. Med. Res. 4, 3 (2017).
Kang, J. W. et al. DAMPs activating innate immune responses in sepsis. Ageing Res. Rev. 24, 54–65 (2015).
Singer, M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 5, 66–72 (2014).
Arulkumaran, N. et al. Mitochondrial function in sepsis. Shock 45, 271–281 (2016).
Buechler, C., Pohl, R. & Aslanidis, C. Pro-resolving molecules - new approaches to treat sepsis? Int. J. Mol. Sci. 18, E476 (2017).
Shankar-Hari, M. & Rubenfeld, G. D. Understanding long-term outcomes following sepsis: implications and challenges. Curr. Infect. Dis. Rep. 18, 37 (2016).